ABOUT EVENT
Why Attend the Innovation in Obesity Therapeutics Summit?
Building on a surge in clinical trial results, including Novo Nordisk's Amycretin with late-stage trials showing a 22% weight loss in Phase 2, the obesity therapeutic landscape is delving into more wide-ranging target approaches alongside these highly well-known therapeutics. This Summit will dissect the future of obesity drug discovery, development, and clinical application beyond GLP-1s.
- Propel your drug development programs forward by exploring novel targets and mechanisms, with the advantage of exploring the latest research and preclinical insights to drive the next generation of obesity therapeutics
- Ensure long-term treatment engagement and patient comfort using muscle-preserving and tolerability-driven approaches into your development programs, with the advantage of designing therapies that enhance patient safety
- Accelerate patient-focussed innovation by bridging the gap between preclinical discovery and clinical success, with the advantage of evaluating innovative therapeutic modalities and administration systems that bring more effective treatments to market faster
This is your opportunity to be at the forefront of obesity drug development as the therapeutic potential for metabolic health expands, accelerating the development of life-changing treatments for millions affected globally.
"Broad perspective on the future of obesity treatments from both scientific presenters and service providers"
Boehringer Ingelheim
Join Your Peers To
Uncover the next generation of obesity therapeutics by exploring novel targets and mechanisms beyond GLP-1s, leveraging cutting-edge research in adipose tissue biology and controlled metabolic accelerators to drive profound and sustained weight loss
Redefine success in obesity care by moving beyond the scale and focusing on a higher quality of weight loss, learning how to leverage muscle-preserving therapies and new body composition readouts to elevate metabolic health
Elevate patient experience and adherence by exploring cutting-edge solutions for improved tolerability and flexible dosing regimens, ensuring long-term treatment engagement that is both effective and patient-centric
Accelerate the pipeline from bench to bedside by bridging the gap between preclinical discovery and clinical success through the analysis of innovative therapeutic modalities, from long-acting antibodies to oral formulations
Harness the power of synergy by discovering how to combine multiple therapeutic pathways with multi-agonist therapies and combination regimens to achieve greater efficacy and tackle the challenges of tolerability, muscle loss and administration routes for obesity
Explore the Full Event Guide
- 60+ Leading Scientists & Drug Development Experts Sharing Groundbreaking Research & Strategies
- 1 Pre-Conference Focus Day
- 10+ Hours of Networking with 60+ Likeminded Obesity Peers
Who You Will Meet
The 2nd Innovation in Obesity Therapeutics Summit is the definitive meeting for 60+ senior leaders across biopharma, innovative biotech, and academia. The audience includes pioneering scientists in metabolic disease, drug discovery, and clinical development experts. This is your exclusive opportunity to gain unparalleled insights from a diverse roster of 18+ renowned speakers and connect with key decision-makers from leading companies in obesity therapeutics, such as Eli Lilly, Boehringer Ingelheim, Supercede Therapeutics and Veru who are shaping the future of innovative obesity treatments.
